Claims for Patent: 8,658,615

Summary for Patent: 8,658,615

Title:	Prohibitin as target for cancer therapy
Abstract:	The present invention relates to pharmaceutical compositions comprising inhibitors of Prohibitin (PHB) for the prevention or/and treatment of hyperproliferative disorders.
Inventor(s):	Rajalingam; Krishnaraj (Berlin, DE), Rudel; Thomas (Berlin, DE)
Assignee:	AEterna Zentaris GmbH (Frankfurt, DE)
Application Number:	13/275,666
Patent Claims:	1. A method for reducing hyper activation of the Ras-MAPK cascade by inhibition of prohibitin over-expression in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a compound which inhibits Prohibitin (PHB) together with pharmaceutically acceptable carriers, adjuvants, diluents or/and additives. 2. The method as claimed in claim 1, wherein said patient is suffering from metastatic tumors, benign tumors, carcinoma, neoplastic carcinoma, gastric carcinoma, larynx carcinoma, neoplastic thyroid cancer, hepatocellular carcinoma, hyperplasia, adenocarcinoma, bladder carcinoma, EGFR overexpressing tumors, Her-2 family overexpressing tumors, Herceptin resistant tumors, B-Raf transformed tumors, or/and Raf-1 transformed tumors. 3. The method as claimed in claim 1, wherein the compound which inhibits Prohibitin (PHB), specifically inhibits the interaction of PHB with a Raf kinase. 4. The method as claimed in claim 3, wherein the compound which inhibits Prohibitin (PHB), specifically inhibits the binding of PHB to a Raf kinase. 5. The method according to claim 4, wherein said Raf kinase is Raf-1. 6. The method as claimed in claim 1, wherein the compound which inhibits Prohibitin (PHB) inhibits activation of the Ras-Raf signalling pathway. 7. The method as claimed in claim 1, wherein the compound which inhibits Prohibitin (PHB) specifically disrupts a Ras-Raf interaction. 8. The method as claimed in claim 1, wherein the compound which inhibits Prohibitin (PHB) inhibits downstream of members of the EGFR family. 9. The method as claimed in claim 1, wherein the compound which inhibits Prohibitin (PHB) converts tumor cells from a transformed to a non-transformed phenotype in vitro and in vivo. 10. The method as claimed in claim 1, wherein the compound which inhibits Prohibitin (PHB) prevents angiogenesis in tumors. 11. The method as claimed in claim 1, wherein the compound which inhibits Prohibitin (PHB) prevents cell migration in vitro or/and in vivo. 12. The method as claimed in claim 1, wherein the compound which inhibits Prohibitin (PHB) down regulates PHB transcription or/and translation, inhibits targeting of PHB to membranes, inhibits targeting of a Raf kinase, or/and inhibits posttranslational modification of PHB. 13. The method as claimed in claim 1, wherein the at least one inhibitor is selected from the group of nucleic acids, nucleic acid analogues, peptides, polypeptides, and antibodies. 14. The method as claimed in claim 13, wherein the nucleic acid is selected from the group consisting of (i) an RNA molecule capable of RNA interference, (ii) a precursor of the RNA molecule (i), and (iii) a DNA molecule encoding the RNA molecule (i) or the precursor (ii). 15. The method as claimed in claim 14, wherein the DNA molecule is a vector. 16. The method as claimed in claim 1, wherein the nucleic acid is a double-stranded RNA molecule with or without a single-stranded overhang alone at one end or at both ends. 17. The method according to claim 6, wherein the compound which inhibits Prohibitin (PHB) inhibits activation of the Ras-Raf-MAPK pathway or/and the PHB dependent branch of the Ras signalling pathway. 18. The method according to claim 8, wherein the compound which inhibits Prohibitin (PHB) inhibits downstream of EGFR and Her-2. 19. The method according to claim 12, wherein the compound which inhibits Prohibitin (PHB) inhibits targeting of Raf-1 (C-Raf) to membranes. 20. The method according to claim 12, wherein the compound which inhibits Prohibitin (PHB) inhibits posttranslational modification of PHB required for the PHB targeting to membranes or/and required for the targeting of a Raf kinase. 21. The method according to claim 20, wherein the compound which inhibits Prohibitin (PHB) inhibits posttranslational modification of PHB required for the targeting of Raf-1 (C-Raf) to membranes. 22. The method according to claim 13, wherein the nucleic acid analogue is a ribozyme. 23. The method as claimed in claim 16, wherein the double-stranded RNA molecule is a double-stranded siRNA molecule. 24. The method according to claim 1, wherein said compound which inhibits Prohibitin is selected from the group consisting of nucleic acids, nucleic acid analogues, antibodies, peptides and polypeptides, wherein said peptides and polypeptides are immunogenic fragments of SEQ ID NO:2 or a Raf kinase and have a length of at least 5 amino acid residues. 25. The method according to claim 1, wherein said compound which inhibits Prohibitin is selected from the group consisting of siRNAs, small molecules, and antibodies.

Details for Patent 8,658,615

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-09-23
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-09-23